(Boursier.com) — Affluent Medicala French MedTech company in the clinical phase specializing in the international development and industrialization of innovative medical prostheses, today publishes its annual results for 2023 and provides an update on the development of its clinical studies.
The year 2023 was marked by several important key milestones in the advancement of the various clinical studies, with the start of the pilot study on Epygon, the excellent clinical results on Kalios in terms of efficacy and safety profile at a year, and also the strengthening of the Management Committee to prepare the different sequences until marketing.
At the same time, the company successfully completed a new financing operation in the form of a capital increase with maintenance of the preferential subscription rights carried out by issuing shares accompanied by redeemable share subscription warrants for a gross amount of 13.7 ME and with the acquisition of 10% of the capital by LCEA. The evolution of operating expenses at the end of 2023 reflects the strengthening of the Group’s workforce with the recruitment of new members of the management committee and external expenses within the framework the development of the various clinical programs in progress. At the end of the financial year, the company had an average workforce of 59 employees compared to 54 people at the end of 2022.
Depreciation allocations cover in particular allocations relating to technologies developed internally.
The financial result as of December 31, 2023 includes in particular the interest paid and the balance of the amortized cost of bond loans for -0.4 ME.
The net result is a loss of 15.6 ME relatively stable compared to the net result of 2022.
©2024 Boursier.com